Bristol Myers Squibb Announces First Disclosure Of Primary Analysis Results Of MZL Cohort Of TRANSCEND FL, Phase 2, Single-Arm Study Evaluating Breyanzi In Patients With Relapsed Or Refractory Disease

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months

New data show liso-cel demonstrated high rates of durable responses and a consistent safety profile in a fifth cancer type, the most of any CD19-directed CAR T cell therapy

Additional liso-cel data at ICML 2025 further reinforce BMS' commitment to unlocking the full potential of this therapy for patients

Bristol Myers Squibb (NYSE:BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will be presented at the 2025 International Conference on Malignant Lymphoma (ICML) in an oral presentation on June 19, building on positive topline results announced in February.